FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

Researchers called for standardized health outcome descriptors to help bridge communication gaps in rheumatology care and ...

Caregivers and patients with acute leukemia face unique challenges, prioritizing treatment preferences that impact quality of ...

The findings suggest a role for assessment of variant-carrying status to predict disease progression in idiopathic pulmonary fibrosis (IPF).

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal ...

Revumenib, an oral targeted therapy for rare leukemias, is projected to be cost-neutral for health plans over 3 years, ...